What's Happening?
Immuto Scientific, an AI-enabled therapeutics company, has presented preclinical findings identifying 16 potential cell-surface targets for KRAS-mutant colorectal cancer (CRC) using its structural surfaceomics platform. This research, conducted in collaboration
with the University of Wisconsin-Madison, compared patient-derived KRAS-mutant colorectal cancer models with healthy colon organoids. Immuto's platform revealed a distinct structural landscape in the cancer models, highlighting shared disease-associated features despite individual patient differences. The study integrated measurements of protein abundance, cell-surface presence, and structure to prioritize these targets. The findings were presented at the 38th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics in Barcelona.
Why It's Important?
The identification of these novel cell-surface targets offers new opportunities for developing more precise antibody-based medicines for KRAS-mutant colorectal cancer, a type of cancer often challenging to treat. Traditional target discovery methods, which primarily rely on protein abundance, can be limited as many established targets show little differentiation between cancerous and healthy cells based solely on abundance. Immuto's structural surfaceomics platform overcomes this limitation by incorporating protein structure, revealing disease-specific structural features that can be targeted. This approach allows for the development of therapies that are more selective for cancer cells, potentially leading to improved efficacy and reduced side effects for patients. The success of this platform has already led to a new internal program in Immuto's pipeline, demonstrating its potential to translate biological insights into therapeutic opportunities.
What's Next?
The 16 identified targets will undergo further investigation as candidates for antibody-based medicines. Immuto Scientific plans to advance its proprietary pipeline of antibody therapeutics, with an initial focus on oncology, and continue partnered programs with pharmaceutical companies. The company's AI-enabled platform will be used to prioritize targets, build conformational models informed by empirical data, and optimize antibodies for affinity and developability. This ongoing work aims to translate these preclinical findings into clinical development, ultimately bringing new treatment options to patients with KRAS-mutant colorectal cancer. The research also supports the broader application of structural surfaceomics for discovering disease-specific targets in other challenging diseases.
Beyond the Headlines
This advancement represents a significant step forward in precision oncology, moving beyond traditional genomic and expression-based approaches to focus on the structural changes of proteins on the cell surface. The ability to identify disease-specific structural targets opens up a new frontier in drug discovery, particularly for cancers with complex molecular profiles like KRAS-mutant CRC. This methodology could lead to a paradigm shift in how therapeutic targets are identified and validated, emphasizing the importance of protein conformation in disease pathology. The integration of AI in this process further highlights the transformative potential of computational tools in accelerating and refining drug development, offering hope for more effective and personalized cancer treatments in the future.













